Phaseline

Companies › GeneMedicine

GeneMedicine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GM103
Intratumoral injection agent
–Phase 1Head and Neck CancerOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06265025GM103Phase 1Head and Neck CancerOncologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.